CI indicates confidence interval; GVHD, graft-versus-host disease; ab-negative, patient does not have anti-HLA antibody; ab-positive, patient has anti-HLA antibody but the CB does not have the corresponding antigen for the antibody specificity; and positive-vs-CB, patient has anti-HLA antibody and the CB has the corresponding antigen for the antibody specificity.

For neutrophil recovery, other significant variables were CD34⁺ cell dose ≤ 0.85 × 10⁵/kg, no usage of G-CSF, advanced disease status and diagnosis of MDS or AML with multilineage dysplasia.

For platelet recovery, other significant variables were advanced disease status, CD34⁺ cell dose ≤ 0.85 × 0⁵/kg and GVHD prophylaxis without MTX.

For acute GVHD of grade II-IV, other significant variables were diagnosis of lymphoproliferative disease and CD34⁺ cell dose ≤ 0.85 × 10⁵/kg.

For relapse, other significant variables were advanced disease status and patient's sex being male.

For transplant-related mortality, other significant variables were patient age more than 45 years at transplantation, GVHD prophylaxis without MTX and cyclosporin-based GVHD prophylaxis compared with tacrolimus-based GVHD prophylaxis.

For treatment failure (as a reverse of event-free survival), other significant variables were advanced disease status, patient age more than 45 years at transplantation, diagnosis of lymphoproliferative disease and GVHD prophylaxis without MTX.

For overall mortality (as a reverse of overall survival), other significant variables were advanced disease status, patient age more than 45 years at transplantation and GVHD prophylaxis without MTX.